CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of heart failures
3.4.1.2. Growing adoption of Point of care testing
3.4.2. Restraints
3.4.2.1. Stringent government regulations
3.4.3. Opportunities
3.4.3.1. Growing awareness of early diagnosis for heart failure
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BNP AND NTPROBNP MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Myocardial Infarction
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Congestive Heart Failure
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Acute Coronary Syndrome (ACS)
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING
5.1. Overview
5.1.1. Market size and forecast
5.2. Point of Care Testing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Laboratory Testing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: BNP AND NTPROBNP MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Application
6.2.3. Market size and forecast, by Location of Testing
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Application
6.2.4.1.3. Market size and forecast, by Location of Testing
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Application
6.2.4.2.3. Market size and forecast, by Location of Testing
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Application
6.2.4.3.3. Market size and forecast, by Location of Testing
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Application
6.3.3. Market size and forecast, by Location of Testing
6.3.4. Market size and forecast, by country
6.3.4.1. UK
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Application
6.3.4.1.3. Market size and forecast, by Location of Testing
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Application
6.3.4.2.3. Market size and forecast, by Location of Testing
6.3.4.3. Germany
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Application
6.3.4.3.3. Market size and forecast, by Location of Testing
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Application
6.3.4.4.3. Market size and forecast, by Location of Testing
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Application
6.3.4.5.3. Market size and forecast, by Location of Testing
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Application
6.3.4.6.3. Market size and forecast, by Location of Testing
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Application
6.4.3. Market size and forecast, by Location of Testing
6.4.4. Market size and forecast, by country
6.4.4.1. China
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Application
6.4.4.1.3. Market size and forecast, by Location of Testing
6.4.4.2. India
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Application
6.4.4.2.3. Market size and forecast, by Location of Testing
6.4.4.3. Australia
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Application
6.4.4.3.3. Market size and forecast, by Location of Testing
6.4.4.4. Japan
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Application
6.4.4.4.3. Market size and forecast, by Location of Testing
6.4.4.5. Rest of Asia-Pacific
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Application
6.4.4.5.3. Market size and forecast, by Location of Testing
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Application
6.5.3. Market size and forecast, by Location of Testing
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Application
6.5.4.1.3. Market size and forecast, by Location of Testing
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Application
6.5.4.2.3. Market size and forecast, by Location of Testing
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Application
6.5.4.3.3. Market size and forecast, by Location of Testing
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Application
6.5.4.4.3. Market size and forecast, by Location of Testing
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1. Quidel Corporation
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.2. Scripps Laboratories
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.3. Gentian Diagnostics ASA
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Siemens AG
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.6. Biomerieux SA
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.7. PerkinElmer Inc.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.8. F Hoffman La Roche Ltd.
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.9. Bio-Rad Laboratories, Inc.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.10. Abbott Laboratories
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 02. BNP AND NTPROBNP MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2021-2031 ($MILLION)
TABLE 03. BNP AND NTPROBNP MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021-2031 ($MILLION)
TABLE 04. BNP AND NTPROBNP MARKET FOR ACUTE CORONARY SYNDROME (ACS), BY REGION, 2021-2031 ($MILLION)
TABLE 05. BNP AND NTPROBNP MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. GLOBAL BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 07. BNP AND NTPROBNP MARKET FOR POINT OF CARE TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 08. BNP AND NTPROBNP MARKET FOR LABORATORY TESTING, BY REGION, 2021-2031 ($MILLION)
TABLE 09. BNP AND NTPROBNP MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 10. NORTH AMERICA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 11. NORTH AMERICA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 12. NORTH AMERICA BNP AND NTPROBNP MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. U.S. BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 14. U.S. BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 15. CANADA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 16. CANADA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 17. MEXICO BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 18. MEXICO BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 19. EUROPE BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 20. EUROPE BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 21. EUROPE BNP AND NTPROBNP MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. UK BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 23. UK BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 24. FRANCE BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 25. FRANCE BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 26. GERMANY BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 27. GERMANY BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 28. ITALY BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 29. ITALY BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 30. SPAIN BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 31. SPAIN BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 32. REST OF EUROPE BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 33. REST OF EUROPE BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 34. ASIA-PACIFIC BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 35. ASIA-PACIFIC BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 36. ASIA-PACIFIC BNP AND NTPROBNP MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. CHINA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 38. CHINA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 39. INDIA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 40. INDIA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 41. AUSTRALIA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 42. AUSTRALIA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 43. JAPAN BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 44. JAPAN BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 45. REST OF ASIA-PACIFIC BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 47. LAMEA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 48. LAMEA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 49. LAMEA BNP AND NTPROBNP MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 50. BRAZIL BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 51. BRAZIL BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 52. SAUDI ARABIA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 53. SAUDI ARABIA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 54. SOUTH AFRICA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 55. SOUTH AFRICA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 56. REST OF LAMEA BNP AND NTPROBNP MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 57. REST OF LAMEA BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021-2031 ($MILLION)
TABLE 58. QUIDEL CORPORATION: KEY EXECUTIVES
TABLE 59. QUIDEL CORPORATION: COMPANY SNAPSHOT
TABLE 60. QUIDEL CORPORATION: PRODUCT SEGMENTS
TABLE 61. QUIDEL CORPORATION: PRODUCT PORTFOLIO
TABLE 62. SCRIPPS LABORATORIES: KEY EXECUTIVES
TABLE 63. SCRIPPS LABORATORIES: COMPANY SNAPSHOT
TABLE 64. SCRIPPS LABORATORIES: PRODUCT SEGMENTS
TABLE 65. SCRIPPS LABORATORIES: PRODUCT PORTFOLIO
TABLE 66. GENTIAN DIAGNOSTICS ASA: KEY EXECUTIVES
TABLE 67. GENTIAN DIAGNOSTICS ASA: COMPANY SNAPSHOT
TABLE 68. GENTIAN DIAGNOSTICS ASA: PRODUCT SEGMENTS
TABLE 69. GENTIAN DIAGNOSTICS ASA: PRODUCT PORTFOLIO
TABLE 70. GENTIAN DIAGNOSTICS ASA: KEY STRATERGIES
TABLE 71. SIEMENS AG: KEY EXECUTIVES
TABLE 72. SIEMENS AG: COMPANY SNAPSHOT
TABLE 73. SIEMENS AG: PRODUCT SEGMENTS
TABLE 74. SIEMENS AG: PRODUCT PORTFOLIO
TABLE 75. DANAHER CORPORATION: KEY EXECUTIVES
TABLE 76. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 77. DANAHER CORPORATION: PRODUCT SEGMENTS
TABLE 78. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 79. BIOMERIEUX SA: KEY EXECUTIVES
TABLE 80. BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 81. BIOMERIEUX SA: PRODUCT SEGMENTS
TABLE 82. BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 83. PERKINELMER INC.: KEY EXECUTIVES
TABLE 84. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 85. PERKINELMER INC.: PRODUCT SEGMENTS
TABLE 86. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 87. F HOFFMAN LA ROCHE LTD.: KEY EXECUTIVES
TABLE 88. F HOFFMAN LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 89. F HOFFMAN LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 90. F HOFFMAN LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 91. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 92. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 93. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 94. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 95. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 96. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 97. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 98. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. BNP AND NTPROBNP MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF BNP AND NTPROBNP MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN BNP AND NTPROBNP MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALBNP AND NTPROBNP MARKET
FIGURE 10. BNP AND NTPROBNP MARKET, BY APPLICATION, 2021 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR MYOCARDIAL INFARCTION, BY COUNTRY 2021-2031 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY 2021-2031 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR ACUTE CORONARY SYNDROME (ACS), BY COUNTRY 2021-2031 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR OTHERS, BY COUNTRY 2021-2031 (%)
FIGURE 15. BNP AND NTPROBNP MARKET, BY LOCATION OF TESTING, 2021 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR POINT OF CARE TESTING, BY COUNTRY 2021-2031 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BNP AND NTPROBNP MARKET FOR LABORATORY TESTING, BY COUNTRY 2021-2031 (%)
FIGURE 18. BNP AND NTPROBNP MARKET BY REGION, 2021
FIGURE 19. U.S. BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 20. CANADA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 21. MEXICO BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 22. UK BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 23. FRANCE BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 24. GERMANY BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 25. ITALY BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 26. SPAIN BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 27. REST OF EUROPE BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 28. CHINA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 29. INDIA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 30. AUSTRALIA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 31. JAPAN BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 33. BRAZIL BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 34. SAUDI ARABIA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 35. SOUTH AFRICA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 36. REST OF LAMEA BNP AND NTPROBNP MARKET, 2021-2031 ($MILLION)
FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 41. COMPETITIVE DASHBOARD
FIGURE 42. COMPETITIVE HEATMAP: BNP AND NTPROBNP MARKET
FIGURE 43. TOP PLAYER POSITIONING, 2021
FIGURE 44. QUIDEL CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 45. QUIDEL CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 46. QUIDEL CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 47. GENTIAN DIAGNOSTICS ASA: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 48. GENTIAN DIAGNOSTICS ASA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 49. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 52. DANAHER CORPORATION: NET SALES, 2019-2021 ($MILLION)
FIGURE 53. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 54. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 55. BIOMERIEUX SA: NET SALES, 2019-2021 ($MILLION)
FIGURE 56. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 57. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 58. PERKINELMER INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 59. PERKINELMER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 60. PERKINELMER INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 62. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. BIO-RAD LABORATORIES, INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 66. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 67. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
FIGURE 68. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 69. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
Executive Summary
According to the report titled, “BNP And NT-proBNP Market," the BNP and NT-proBNP market was valued at $1.1 billion in 2021, and is estimated to reach $3.4 billion by 2031, growing at a CAGR of 12.2% from 2022 to 2031.
BNP and NT-proBNP are peptide hormones and are commonly used as biomarkers in the diagnosis and management of heart failure. These hormones are produced by the heart in response to increased pressure and stretching of heart muscle cells. The elevated levels of BNP and NT-proBNP in the blood indicate heart failure. Thus, BNP and NT-proBNP tests are used to diagnose and manage various cardiovascular conditions such as heart failure, myocardial infarction, and others. The early diagnosis of cardiovascular diseases is crucial to improve patient outcomes and reducing the overall cost of care. Therefore, BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) are widely used as the most promising biomarkers for the diagnosis of various cardiovascular diseases.
Key factors driving the growth of the BNP and NT-proBNP market include an increase in the prevalence of heart failure as heart failure is a common and serious condition, which drives the demand for BNP and NT-proBNP tests for diagnosis and management of diseases and advancements in diagnostic technologies such as high-sensitivity BNP and NT-proBNP assays. For instance, Abbott’s ARCHITECT high Sensitive BNP assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of human B-type natriuretic peptide (BNP) in humans. It offers improved accuracy, sensitivity, and specificity, and is used for the early detection of heart failure and for evaluating the efficacy of treatment. In addition, Roche’s Elecsys proBNP II assay is indicated for the risk stratification of patients with acute coronary syndrome, and congestive heart failure (CHF), and it is also used for monitoring the treatment in patients with left ventricular dysfunction. Therefore, the rise in the prevalence of heart failure and improved accuracy of BNP and NT-proBNP testing propels the growth of the market.
The market also offers growth opportunities to the key players in the market. Rise in awareness about biomarker diagnostic testing as the biomarker tests are non-invasive, provides quick results allow for prompt diagnosis and treatment, and biomarker testing is more cost-effective than traditional diagnostic methods and increase in point-of-care testing in developed and developing countries such as U.S. and India expected to create lucrative growth opportunities for market growth. Moreover, the rise in disposable income in India and China also contributes toward the market growth during the forecast period. In addition, the wide availability of BNP and NT-proBNP point-of-care testing which allows for rapid testing at outpatient settings increases the adoption of BNP and NT-proBNP testing.
Moreover, continued advancements in BNP and NT-proBNP testing technology, including the development of high-sensitivity assays and machine learning algorithms, are expected to drive market growth by improving the accuracy and efficiency of testing.
Furthermore, an increase in demand for personalized medicine and growing awareness of the importance of early disease diagnosis are the key factors that drive market growth. For instance, BNP and NT-proBNP tests provide valuable information to guide treatment decisions for heart failure patients, making them an important tool of personalized medicine. Additionally, the demand for BNP and NT-proBNP testing is not only limited to developed countries but is also being witnessed in developing countries, such as China, and India, which fuels the growth of the market. Factors such as a rise in the incidence of heart failure, an increase in the number of the geriatric population more susceptible to cardiovascular diseases, an increase in R&D investments in the discovery & development of novel biomarker-based testing, and rise in awareness regarding early detection of diseases, further drive the growth of the market.
The BNP and NT-proBNP market is segmented on the basis of application, location of testing, and region. On the basis of application, the market is classified into myocardial infarction, congestive heart failure (CHF), acute coronary syndrome (ACS), and others. On the basis of the location of testing, the market is segmented into point-of-care testing and laboratory testing. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Abbott Laboratories, BioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffman La Roche Ltd., Gentian Diagnostics ASA, PerkinElmer Inc., Quidel Corporation, Scripps Laboratories, Siemens AG.
Key Market Insights
- By application, the myocardial infarction segment was the highest revenue contributor to the market in 2021 and is estimated to reach $1.2 billion by 2031.
- By location of testing, the point-of-care testing segment dominated the global market in 2021.
- Based on region, Asia-Pacific garnered the largest revenue share in 2021 and is anticipated to grow at the highest CAGR of 13.5% during the forecast period.
Companies Mentioned
- Scripps Laboratories
- Abbott Laboratories
- Danaher Corporation
- Gentian Diagnostics ASA
- Siemens AG
- PerkinElmer Inc.
- Biomerieux SA
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
- F Hoffman La Roche Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 213 |
| Published | February 2023 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 1.1 billion |
| Forecasted Market Value ( USD | $ 3.4 billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
Related Reports
Chronic Heart Failure - Pipeline Insight, 2024
- Clinical Trials
- 80 Pages
- Global
Pulmonary Arterial Hypertension Market Insight, Epidemiology and Market Forecast - 2034
- Report
- 250 Pages
- Global
